Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Immunovia Interim report, January-March 2017

“During the quarter we reported from a significant study that showed our ability to differentiate between SLE and other common autoimmune diseases. The very good results of the study, which indicated that SLE can be differentiated with 96% accuracy against a mix of healthy, rheumatoid arthritis, Sjögren’s disease and vasculitis patient samples, give us a very strong reason to invest further in the autoimmune area." "Also during the quarter we identified retrospective biobanks that contain relevant and well-documented blood samples from individuals who are afflicted with pancreatic cancer

Atlas Copco to acquire full stake in Taiwanese exhaust management business

Stockholm, Sweden, April 20, 2017: Atlas Copco, a leading provider of sustainable productivity solutions, has agreed to buy the remaining stake in CSKT Inc., a joint venture in Taiwan that sells and services gas abatement and chemical delivery systems.Atlas Copco acquired a 55% stake in CSKT with the acquisition in 2016 of CSK Inc., the South Korean exhaust management company. Atlas Copco is now acquiring the remaining 45%.  “Taiwan is an important market for advanced exhaust management, and the strong team at CSKT will continue to help us increase customers’ productivity,” said Geert

NOTE’s Interim Report January–March 2017

Financial performance January–March · Sales were SEK 277.1 (279.1) million. Excluding divestments, sales increased by 4%. · Operating profit was SEK 30.4 (14.2) million, and adjusted for non-recurring items, operating profit increased to SEK 14.7 (14.2) million. · Operating margin was 11.0% (5.1%), and adjusted for non-recurring items, operating margin expanded by 0.2 percentage points to 5.3% (5.1%). · Profit after financial items increased to SEK 29.1 (12.9) million. · Profit after tax was up to SEK 26.9 (10.2) million, corresponding to SEK 0.93 (0.35) per share. ·

Episurf Medical AB’s 2016 annual report is now available

Episurf Medical’s annual report for 2016 is available as of today at the company’s website, www.episurf.com. Episurf Medical has of environmental and cost reasons chosen not to print the annual report. A printed version of the annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical AB Karlavägen 60 114 49 Stockholm Sweden Or by email: ir@episurf.com For more information, please contact: Pål Ryfors, acting CEO, Episurf Medical  Tel: +46

INVISIO: Invitation to Q1 2017 conference call on April 27 at 10.00 CET

Stockholm, April 20, 2017  INVISIO is pleased to invite press, investors and analysts to a conference call on April 27, 2017 at 10.00 CET where CEO Lars Højgård Hansen and CFO Thomas Larsson present the INVISIO 2017 first quarter results.The conference call, which will be held in English, will begin with a presentation of the interim results followed by a Q&A session.The interim report for January-March 2017 will be announced on April 26.Phone number for the conference:To participate in the conference call, use the dial-in numbers below. Please dial in 5-10 minutes prior to the

Enzymatica AB: Breakthrough in Germany and continued increase in sales

INTERIM REPORT FORENZYMATICA AB (publ)JANUARY-MARCH 2017 Breakthrough in Germany and continued increase in sales First quarter · Net sales reached SEK 9.6 (8.4) million. · Loss after tax came in at SEK -11.4 (-8.1) million. · Earnings per share were SEK -0.13 (-0.32). · Cash and cash equivalents were SEK 26.0 (7.2) million at the end of the quarter. Significant events during the quarter · Enzymatica entered into an exclusive distribution agreement with STADA Arzneimittel AG for distribution of ColdZyme[® ]in the German market. Key figures(SEK million)

Biohit Oyj B-shares subscribed with Stock Options I 2013 B

Biohit Oyj Total number of voting rights and capital April 20, 2017 at 9:30 am (EEST) A total number of 21 858 new Biohit Oyj B-shares have been subscribed for with stock options I 2013 B between 2 December 2016 and 9 March 2017. These shares have been entered into the trade register on April 20, 2017, as of which date the new shares will establish equal shareholder rights with the company's existing B-shares. Public trading is expected to begin on NASDAQ Helsinki as of April 21, 2017 together with the existing B-shares. The share subscription price was EUR 2.2766 per share

Episurf Medical AB (publ) brings forward interim report

Due to planning for the upcoming Annual General Meeting on May 22, 2017, Episurf Medical will bring forward its reporting date for the first quarter 2017 to May 15, 2017, 08:30 CET. For more information, please contact: Pål Ryfors, acting CEO, Episurf Medical  Tel: +46 (0) 709 62 36 69Email: pal.ryfors@episurf.com About Episurf Medical Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized

Strong first quarter for Södra

Södra’s operating profit totalled SEK 451 million (249) for the first quarter. The operating margin improved to 9 percent (5) and return on capital employed to 11 percent (7).“Södra’s first quarter was strong with increased net sales, higher earnings and an improved operating margin. Robust demand contributed to the favourable volume and price trend, and the currency trend was also positive. Based on its Group strategy, Södra will continue to strengthen and focus on increased digitisation, innovation and sustainability,” said Lars Idermark, President and CEO. “One important reason for

Interim Report January-March 2017

First quarter 2017 compared to first quarter 2016 · Customer growth remained strong and the number of new customers was 38,400 (26,100) · Net inflow in the quarter was SEK 8,620 million, an increase of 74 per cent · Operating income increased by 9 per cent, mainly due to higher fund volumes and currency-related income as well as good activity within corporate transactions · Operating expenses increased by 13 per cent, mainly due to an increased number of employees in IT and product development · Net profit of SEK 103 million, an increase of 5 per cent, mainly due to higher

Mycronic’s all new MY700 high-speed jet dispenser marks launch of next-generation MYPro series

Täby, 20 April, 2017 – Mycronic AB (publ) launches the new MY700 high-speed jet dispenser, for jet printing of solder paste and dispensing of assembly fluids, at NEPCON China in Shanghai, April 25-27, 2017. The MY700 is the first release in Mycronic’s next-generation MYPro series product lineup and is the result  of Mycronic’s strategy of organic growth to meet the electronic industry’s needs for advanced production equipment enabling the future of electronics. The MY700 will process any type of circuit board, from standard to complex flexible boards, by jetting high-speed, high-

Citycon updates its disclosure policy

CITYCON OYJ      Stock Exchange Release      20 April 2017 at 09:05 hrsCitycon Oyj's disclosure policy has been updated and is now available in English on the company's website at www.citycon.com/disclosure-policy. The updates are mainly technical, adopting recent regulation change related new interpretations by authorities.Helsinki, 20 April 2017CITYCON OYJHenrica GinströmVice President, Investor Relations and CommunicationsTel. +358 50 554 4296henrica.ginstrom@citycon.comCitycon is an owner, developer and manager of urban grocery-anchored shopping centres in the Nordic and

Reminder: invitation to presentation of Bonava’s first quarter 2017

Bonava AB (publ) will publish its first quarterly report for 2017 on April 27 at 8:00 a.m. CET. The report will be presented to investors, analysts and the media at Bonava’s headquarter on April 27 at 10:00 a.m.Venue: Bonava’s headquarter, Lindhagensgatan 72, Stockholm, Sweden. Date and time: Thursday, April 27, 10:00–11:00 a.m. Registration and coffee served from 9:30 a.m. Program: Joachim Hallengren, CEO and Ann-Sofi Danielsson, CFO and Head of Investor Relations will present the first quarter 2017. The presentation will end with a Q&A. Registration: Register by e-mail at ir@

SKF’s first quarter results to be published on 27 April 2017

Gothenburg, 20 April 2017: The SKF Group will publish its results for the first quarter on 27 April 2017 and welcomes investors, analysts and members of the media to take part in a conference call, which will be held in English, at 09:00 (CET), 08:00 (UK time). To join the conference call, please dial-in using the following details at least 10 minutes before the start of the call: SE: +46 (0)8 5876 9445UK: +44 (0)20 3427 1914US: +1 212 444 0481 Please inform the operator that you wish to take part in the SKF conference call.   The SKF Group's results for the first quarter

Tieto helping University of Gävle to introduce a new document management system

Tieto is helping the University of Gävle to introduce a new document management system. The agreement Tieto will deliver a standardised solution for document and case management which will digitalise the handling of regulatory documents and simplify daily operations for around 700 employees. The new solution Public 360° will support the introduction of an integrated management system at the University of Gävle, which has about 17,000 students. The contract runs over four years. ”A modern university needs digital tools that support our daily work in the best possible way. Tieto’s

Mycronic, first quarter January-March, 2017

Mycronic reports growth in all market segments for the first quarter Mycronic's net sales rose 97 percent compared to the first quarter of 2016. The underlying EBIT margin amounted to 31 percent. "Growth in the quarter proves that our product offering meets the customers’ challenges," says Lena Olving, President and CEO. First quarter January-March 2017 · Order intake reached SEK 653 (794) million · Net sales reached SEK 676 (344) million · EBIT was SEK 159 (32) million · Underlying EBIT was SEK 208 (32) million · Earnings per share was SEK 1.15 (0.24) Outlook 2017

JM Construction building residential units in Tyresö, Stockholm

JM Construction has signed an agreement with Småa to construct tenant-owned apartments, townhouses and premises through a turnkey contract. The total contract amounts to SEK 113m.The contract comprises new production of 38 apartments, 9 townhouses and 3 additional premises. Establishment and ground work are scheduled for June 2017, and the project is expected to be completed by Q3 2019. The project will be constructed in accordance with the Silver level in the Swedish Green Building Council's classification system. “We are very pleased that Småa has entrusted us with the Grönskan project,

GBO's offer for Vigmed: Supplement to the offer document made public

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important notice” at the end of this

NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects

Lund, Sweden, 20 April 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) (“NeuroVive”) today announced positive preclinical results demonstrating anti-fibrotic effects with NV556, the company’s preclinical compound for non-alcoholic steatohepatitis (NASH), in an additional well-validated experimental NASH model.NV556 has previously shown similar anti-fibrotic effects in the experimental STAM™ NASH model. Today, NeuroVive’s scientists present novel data demonstrating anti-fibrotic effects of NV5556 also in the experimental MCD NASH model, strengthening and confirming

Citycon Q1: Good start to the year – EPRA Earnings growth fuelled by Sweden and Norway

Citycon Oyj      Interim Report      20 April 2017 at 09:00 hrsJANUARY—MARCH 2017-Net rental income increased to EUR 56.6 million (Q1/2016: 55.2) mainly due to (re)development projects coming online (mainly Iso Omena) and the acquisition of the adjacent building to Citycon’s Oasen shopping centre in Bergen, Norway. In addition, positive like-for-like growth contributed to net rental income growth by EUR 0.5 million. The non-core property divestments in 2016 and 2017 decreased net rental income by EUR 2.0 million.-EPRA Earnings increased by EUR 2.4 million, or 6.6%, to EUR 38.3 million,

Interim Report Q1 2017

Financial overview Q1 2017 · Total net revenues SEK 127.4 million (151.0) · Zubsolv® net revenue SEK 114.1 million (98.4) · EBIT SEK -23.2 million (-26.2) · EBITDA SEK -18.1 million (-19.4) · Earnings per share, before and after dilution, SEK -1.00/-1.00 (-1.00/-1.00) · Cash flow from operating activities SEK 28.2 million (33.5) · Cash and cash equivalents SEK 250.6 million (233.0) · Guidance issued in connection with Full Year Report 2016 confirmed Other highlights Q1 2017 · Completion of another bond buyback program amounting to a nominal value of SEK 59

Evolution Gaming: Interim report January-March 2017

First quarter of 2017 (Q1 2016) · Operating revenues increased by 60% to EUR 39.7 million (24.8) · EBITDA increased by 65% to EUR 17.0 million (10.3), corresponding to a margin of 43% (42) · Profit for the period amounted to EUR 12.7 million (7.6) · Earnings per share amounted to EUR 0.35 (0.21) Events during the first quarter of 2017 · Overall very high demand for Live Casino games among the customers · Agreement with the Spanish gaming operator Codere for exclusive provision of Live Casino in Mexico · Additional new agreements with mybet, Matchbook and White

Skanska leases office space in Generation Park in Warsaw, Poland, to Citi Service Center Poland

Skanska has leased 13,600 square meters of office space in phase I of Generation Park in Warsaw, Poland, to Citibank Europe PLC (Citi Service Center Poland). The start date of the lease is scheduled for the fourth quarter of 2017.The first phase of Generation Park is already over 70 percent leased to three tenants. Citibank will occupy about 60 percent of phase I. Generation Park will be Skanska’s largest office development in Central and Eastern Europe. The complex will comprise of three office buildings with total leasable area of around 84,000 square meters. The project is expected to

There are no items matching the current filter
There are no more items matching the current filter
Back to top